Our expert scientists. Your custom assay.
Understanding how to use Oligodendrocyte Precursor Cells (OPCs) to enhance remyelination in multiple sclerosis is key to bringing new treatments to the clinic.
At Aquila, we offer screening using OPCs. By assessing the effect of your drug candidate on OPC proliferation, differentiation and apoptosis, we can help you identify compounds with the potential to enhance myelination, bringing you on the best route to the clinic.
We are also developing a high-throughput 3D OPC culture assay and hope to offer human OPC assays in the near future.
Please get in touch for further information.
